Bain doubles down on Tony Coles’ quest to get a late-stage Parkinson’s drug through to market
Cerevel Therapeutics had a charmed start to its life with the backing of financial giant Bain Capital and a clutch of former Pfizer assets to work with. Now, extending its relationship with Bain, Cerevel has snagged another big check to race its Parkinson’s disease candidate through late-stage studies and on to market.
Bain and NovaQuest will drop $125 million in non-dilutive funding to drive Cerevel’s Phase III program for Parkinson’s drug tavapadon, with up to $531 million in future milestones at stake, the biotech said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.